Le Zhang

Real-world safety profile of alectinib: a 10-year pharmacovigilance study based on the FDA adverse event reporting system

Objective Alectinib is the standard first-line therapy for treatment-naïve ALK-positive non-small cell lung cancer (NSCLC). Given its increasing clinical utilization, a comprehensive pharmacovigilance evaluation of its adverse events (AEs) is warranted. Methods We assessed alectinib-associated AEs using the FDA Adverse...